km-233 and Inflammation

km-233 has been researched along with Inflammation* in 1 studies

Other Studies

1 other study(ies) available for km-233 and Inflammation

Article	Year
Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. Bioorganic & medicinal chemistry letters, 2009, Mar-15, Volume: 19, Issue:6 A novel series of cannabinoid ligands with a structurally unique tri-aryl core has been designed, synthesized and assayed. Receptor binding assays show that these compounds possess CB2 receptor sub-type selectivity with binding affinities ranging from 1.07 (+/-0.05) for 7 to 4.77 (+/-0.57) nM for 6. The selectivity of the compounds was enhanced 9-600-fold for the CB2 receptor over the CB1 receptor. The results of our present study identify a novel, highly selective cannabinoid scaffold with a non-classical core. Topics: Benzophenones; Binding Sites; Cannabinoids; Cell Line; Chemistry, Pharmaceutical; Drug Design; Humans; Inflammation; Kinetics; Ligands; Models, Chemical; Molecular Structure; Receptor, Cannabinoid, CB2; Stereoisomerism; Transfection	2009

Article

Year

Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.

Bioorganic & medicinal chemistry letters, 2009, Mar-15, Volume: 19, Issue:6

A novel series of cannabinoid ligands with a structurally unique tri-aryl core has been designed, synthesized and assayed. Receptor binding assays show that these compounds possess CB2 receptor sub-type selectivity with binding affinities ranging from 1.07 (+/-0.05) for 7 to 4.77 (+/-0.57) nM for 6. The selectivity of the compounds was enhanced 9-600-fold for the CB2 receptor over the CB1 receptor. The results of our present study identify a novel, highly selective cannabinoid scaffold with a non-classical core.

Topics: Benzophenones; Binding Sites; Cannabinoids; Cell Line; Chemistry, Pharmaceutical; Drug Design; Humans; Inflammation; Kinetics; Ligands; Models, Chemical; Molecular Structure; Receptor, Cannabinoid, CB2; Stereoisomerism; Transfection

2009